Safety assessment of Acori Tatarinowii Rhizoma: acute and subacute oral toxicity.
Front Pharmacol
; 15: 1377876, 2024.
Article
in En
| MEDLINE
| ID: mdl-38567357
ABSTRACT
Introduction:
Acori Tatarinowii Rhizoma (ATR) is a well-known traditional Chinese medicine that is used for treating neuropathic diseases. However, there is little information about the safety of ATR.Methods:
The present study evaluated the acute and subacute oral toxicity of a water extract of ATR in Institute of Cancer Research (ICR) mice. In acute trials, a single administration of extract at a dose 5,000 mg/kg body weight led to no clinical signs of toxicity or mortality, indicating that the lethal dose (LD50) exceeded 5,000 mg/kg. A subacute toxicity test was done using daily doses of 1,250, 2,500, and 5,000 mg/kg of the ATR extract for 28 days, which did not show any adverse clinical symptoms or mortality. However, the male renal organ index and urea level in mice given 5,000 mg/kg was obviously abnormal, which was consistent with pathological results and suggested that this dose might cause kidney injury.Results:
Doses of ATR lower than 2,500 mg/kg could be regarded as safe, although the potential cumulative effects of long-term use of high doses of ATR need to be considered.Discussion:
The study highlights the function of ATR in reducing blood lipids and provides a new idea for its widespread clinical use in the future.
Full text:
1
Database:
MEDLINE
Language:
En
Journal:
Front Pharmacol
Year:
2024
Type:
Article
Affiliation country:
China